Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

Ponatinib, the only third‐generation pan‐BCR::ABL1 inhibitor with activity against all known BCR::ABL1 mutations including T315I, has demonstrated deep and durable responses in patients with chronic‐phase chronic myeloid leukemia (CP‐CML) resistant to prior second‐generation (2G) TKI treatment. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop M., Jabbour, Elias, Deininger, Michael, Abruzzese, Elisabetta, Apperley, Jane, Cortes, Jorge, Chuah, Charles, DeAngelo, Daniel J., DiPersio, John, Hochhaus, Andreas, Lipton, Jeffrey, Nicolini, Franck E., Pinilla‐Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Srivastava, Shouryadeep, Ren, Xiaowei, Mauro, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804741/
https://www.ncbi.nlm.nih.gov/pubmed/36054756
http://dx.doi.org/10.1002/ajh.26686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804741/
https://www.ncbi.nlm.nih.gov/pubmed/36054756
http://dx.doi.org/10.1002/ajh.26686

Ejemplares similares